Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Trial Details

NCT ID

NCT06535607

Phase

PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

• Volrustomig
• Cisplatin
• Carboplatin
• Paclitaxel
• 5-FU

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• Baltimore, Maryland, United States|39.29038,-76.61219
• New York, New York, United States|40.71427,-74.00597
• Stony Brook, New York, United States|40.92565,-73.14094
• Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

• Age ≥18 at the time of signing the ICF.
• Provision of tumor sample to assess the PD-L1 expression (if applicable).
• ECOG performance status of 0 or 1.
• Measurable disease according to RECIST 1.1 (variations of RECIST 1.1 if applicable).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.